The first and only IgG Fc-antibody fragment for the treatment of gMG1*
About gMG
Find out more about the burden of gMG symptoms, conventional treatment options and assessment tools
Mechanism of action
Discover the mechanism of action of VYVGART®
VYVGART® (efgartigimod alfa) is indicated for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.1
VYVGART®: recharging the neuromuscular junction
Demonstrated efficacy profile of VYVGART®†
Improvement in daily function:
- 68% (n=44/65) of AChRAb+ patients treated with VYVGART® were responders who experienced improvement in daily function vs. 30% (n=19/64) with placebo (p<0.0001; primary endpoint)‡§
Safety profile of VYVGART®
Evaluate VYVGART® related safety data from the ADAPT and ADAPT+ clinical studies.
Dosing and administration
Read more about VYVGART® dosing and administration
Support and coverage
Review support offered by the MyPATH Patient Support Program, and details related to provincial coverage.
Resources
Access VYVGART® resources for you and your patients.
Looking for information on provincial funding access to VYVGART®?
AChRAb+=acetylcholine receptor antibody-positive; Fc=crystallizable fragment; gMG=generalized Myasthenia Gravis; IgG=immunoglobulin G; MG-ADL=Myasthenia Gravis Activities of Daily Living; Tx=treatment
| * | Comparative clinical significance has not been established. |
| † | See the ADAPT trial design. |
| ‡ | Patients were treated with VYVGART® + current Tx or placebo + current Tx. |
| § | MG-ADL response was defined as a ≥2-point reduction in the total MG-ADL score compared to the treatment cycle baseline for at least 4 consecutive weeks during the first treatment cycle (by Week 8), with the first reduction occurring no later than 1 week after the last infusion of the cycle. |
Reference: 1. VYVGART® Product Monograph. argenx. July 17, 2025.
